Pharmacogenomic decision support database
... genome is known and taken into account when prescribing medical treatment to a patient. Understanding and translating pharmacogenomic information into practice requires a highly sophisticated database. GeneRx is a one-of-a-kind solution that integrates with the electronic health record system (EHR) ...
... genome is known and taken into account when prescribing medical treatment to a patient. Understanding and translating pharmacogenomic information into practice requires a highly sophisticated database. GeneRx is a one-of-a-kind solution that integrates with the electronic health record system (EHR) ...
toxicogenomics and the workplace - University of Virginia School of
... billion per year. It must be assumed that there would be DTC advertising of pharmacogenomicallybased products. ...
... billion per year. It must be assumed that there would be DTC advertising of pharmacogenomicallybased products. ...
Pharmacogenetics
... pharmacologic pathways in statin therapy (previous slide) have an SNP (single nucleotide polymorphism) this will effect the way the drug affect’s the body, thus effecting the RESPONSE of statin in lowering LDL and preventing CVD O A choice of a different statin or another ...
... pharmacologic pathways in statin therapy (previous slide) have an SNP (single nucleotide polymorphism) this will effect the way the drug affect’s the body, thus effecting the RESPONSE of statin in lowering LDL and preventing CVD O A choice of a different statin or another ...
Pharmacogenetics - UCSD Cognitive Science
... person has a disease than to know what sort of disease a person has.” -Hippocrates (460 BC – 370 BC) ...
... person has a disease than to know what sort of disease a person has.” -Hippocrates (460 BC – 370 BC) ...
Document
... - relationship between chemical structure and biologic activity - site of effect localisation - mechanism of action - fate of drug in organism - evaluation of relationship between dose and biologic effect ...
... - relationship between chemical structure and biologic activity - site of effect localisation - mechanism of action - fate of drug in organism - evaluation of relationship between dose and biologic effect ...
CYP2D6 - PGXL Laboratories
... CYP2C19 Poor Metabolizer (PM): This patient’s genotype is consistent with significantly reduced CYP2C19 enzymatic activity. PMs are at increased risk of drug-induced side effects due to diminished drug elimination of active drugs. Patients with no CYP2C19 function (PMs) taking clopidogrel lack adequ ...
... CYP2C19 Poor Metabolizer (PM): This patient’s genotype is consistent with significantly reduced CYP2C19 enzymatic activity. PMs are at increased risk of drug-induced side effects due to diminished drug elimination of active drugs. Patients with no CYP2C19 function (PMs) taking clopidogrel lack adequ ...
An_Analysis_on impact of_Drugs_based on_Genetics_Elsa_Jose
... Drugs & Genetics: Why Do Some People Respond to Drugs Differently than Others? Abstract In a survey conducted from 2007 to 2010, the U.S. Centers for Disease Control and Prevention reported that about 49% of people in the United States had taken at least one prescription drug during the past month, ...
... Drugs & Genetics: Why Do Some People Respond to Drugs Differently than Others? Abstract In a survey conducted from 2007 to 2010, the U.S. Centers for Disease Control and Prevention reported that about 49% of people in the United States had taken at least one prescription drug during the past month, ...
Principles of Pharmacolgy
... Study of actions of the drug & changes that drugs undergo from absorption to excretion Receptor, Agonist, Antagonist propranolol (Inderal) beta adrenergic antagonist ...
... Study of actions of the drug & changes that drugs undergo from absorption to excretion Receptor, Agonist, Antagonist propranolol (Inderal) beta adrenergic antagonist ...
Slides
... Genetic Analysis Permits • More rapid determination of stable therapeutic dose. • Better prediction of dose than clinical methods alone. • Applicable to the 70-75% of patients not in controled anticoagulation centers. • Reduced between 4,500 and 22,000 serious bleeding events annually. • Genetic te ...
... Genetic Analysis Permits • More rapid determination of stable therapeutic dose. • Better prediction of dose than clinical methods alone. • Applicable to the 70-75% of patients not in controled anticoagulation centers. • Reduced between 4,500 and 22,000 serious bleeding events annually. • Genetic te ...
Fact Sheet 21 | PHARMACOGENETICS/PHARMACOGENOMICS
... Factors that influence how an individual responds to medication include their external and internal environments and overall health, as well as their genetic make-up. The goal of pharmacogenomics is to understand the role that an individual’s genetic make-up plays in how well a medicine works, as we ...
... Factors that influence how an individual responds to medication include their external and internal environments and overall health, as well as their genetic make-up. The goal of pharmacogenomics is to understand the role that an individual’s genetic make-up plays in how well a medicine works, as we ...
An Interview with Dr. Marie-Pierre Dubé of the Montreal Heart
... MPD: Because it’s interesting. There is a long history about whether it is a good idea to raise HDL cholesterol; no Phase III trials have proven the hypothesis yet. One compound, dalcetrapib, was efficacious in raising HDL cholesterol in its Phase III trial, but that did not translate into an overal ...
... MPD: Because it’s interesting. There is a long history about whether it is a good idea to raise HDL cholesterol; no Phase III trials have proven the hypothesis yet. One compound, dalcetrapib, was efficacious in raising HDL cholesterol in its Phase III trial, but that did not translate into an overal ...
predict - Vanderbilt University Medical Center
... ABCB1; ABCC2; ABCG2; CYP1A1, CYP1A2; CYP2A6; CYP2B6; CYP2C19; CYP2C8; CYP2C9; CYP2D6; CYP2E1; CYP3A4; CYP3A5; DPYD; GSTM1; GSTP1; CSTT1; NAT1; NAT2; SLC15A2; SLC22A1; SLC22A2; SLC22A6; SLC01B1; SLC01B3; SLC02B1; SULT1A1; TPMT; UGT1A1; UGT2B15; UGT2B17; UGT2B7; VKORC1 ...
... ABCB1; ABCC2; ABCG2; CYP1A1, CYP1A2; CYP2A6; CYP2B6; CYP2C19; CYP2C8; CYP2C9; CYP2D6; CYP2E1; CYP3A4; CYP3A5; DPYD; GSTM1; GSTP1; CSTT1; NAT1; NAT2; SLC15A2; SLC22A1; SLC22A2; SLC22A6; SLC01B1; SLC01B3; SLC02B1; SULT1A1; TPMT; UGT1A1; UGT2B15; UGT2B17; UGT2B7; VKORC1 ...
Concepts and Tools in Pharmacogenomics
... • Stretches of up to 30,000 C and G bases repeating over and over often occur adjacent to gene-rich areas, forming a barrier between the genes and the "junk DNA." These CpG islands are believed to help regulate gene activity. • Chromosome 1 has the most genes (2968), and the Y chromosome has the few ...
... • Stretches of up to 30,000 C and G bases repeating over and over often occur adjacent to gene-rich areas, forming a barrier between the genes and the "junk DNA." These CpG islands are believed to help regulate gene activity. • Chromosome 1 has the most genes (2968), and the Y chromosome has the few ...
Louis Niessen MD PhD Management, Erasmus MC, Erasmus University,
... Economic evaluation of existing and future pharmacogenomics-based treatment strategies: Can there be a generic approach? Ken Redekop, PhD and Louis Niessen, MD, PhD Pharmacogenomics tests help to identify patients who will experience important adverse events or who obtain important benefit from drug ...
... Economic evaluation of existing and future pharmacogenomics-based treatment strategies: Can there be a generic approach? Ken Redekop, PhD and Louis Niessen, MD, PhD Pharmacogenomics tests help to identify patients who will experience important adverse events or who obtain important benefit from drug ...
CYP2D6 - PGXL Laboratories
... Coumadin, to explain that people's genetic makeup may influence how they respond to the drug. ...
... Coumadin, to explain that people's genetic makeup may influence how they respond to the drug. ...
Pharmacogenomics Principles and Concepts
... Division of Pharmacotherapy and Experimental Therapeutics University of North Carolina at Chapel Hill Eshelman School of Pharmacy ...
... Division of Pharmacotherapy and Experimental Therapeutics University of North Carolina at Chapel Hill Eshelman School of Pharmacy ...
Supplementary Figure 1. Distribution of variant properties by gene in
... each gene with allele frequencies (AF) below 0.1% for all 17,758 genes compared to 806 drug-related genes (pharmacogenes); fraction of variants in gene without corresponding entries in dbSNP, thus deemed novel; fraction of variants that result in the loss of the protein product (loss-of-function, Lo ...
... each gene with allele frequencies (AF) below 0.1% for all 17,758 genes compared to 806 drug-related genes (pharmacogenes); fraction of variants in gene without corresponding entries in dbSNP, thus deemed novel; fraction of variants that result in the loss of the protein product (loss-of-function, Lo ...
Pain Management Medications
... Pharmacogenomics is the area of medicine that analyses how the genetic makeup of an individual affects his/her response to drug treatment. Research studies have shown that genetics may account for much of the variability in patients’ responses. In many patients, certain drugs do not work as well as ...
... Pharmacogenomics is the area of medicine that analyses how the genetic makeup of an individual affects his/her response to drug treatment. Research studies have shown that genetics may account for much of the variability in patients’ responses. In many patients, certain drugs do not work as well as ...
Pharmacogenomics and Personalized Medicine
... differences have an effect on (1) drug metabolism (pharmacokinetics) or (2) drug action (pharmacodynamics). Personalized Medicine involves understanding how some genetic markers impact drug safety and efficacy, and PREDICTING how a patient will respond to a specific drug/dose (based on the patient’s ...
... differences have an effect on (1) drug metabolism (pharmacokinetics) or (2) drug action (pharmacodynamics). Personalized Medicine involves understanding how some genetic markers impact drug safety and efficacy, and PREDICTING how a patient will respond to a specific drug/dose (based on the patient’s ...
Biomedical Informatics and Interdisciplinary Research
... differences have an effect on (1) drug metabolism (pharmacokinetics) or (2) drug action (pharmacodynamics). Personalized Medicine involves understanding how some genetic markers impact drug safety and efficacy, and PREDICTING how a patient will respond to a specific drug/dose (based on the patient’s ...
... differences have an effect on (1) drug metabolism (pharmacokinetics) or (2) drug action (pharmacodynamics). Personalized Medicine involves understanding how some genetic markers impact drug safety and efficacy, and PREDICTING how a patient will respond to a specific drug/dose (based on the patient’s ...
Pharmacogenomics: The Future of Personalized Medicine
... This patient most likely has a CYP2D6 and CYP2C9 polymorphism The CYP2C9 polymorphism decreases her metabolic rate of coumadin, leading to a lower dose requirement for her goal INR of 2-3 The analgesic effect of morphine is decreased in CYP2D6 polymorphisms so she will require an analgesic tha ...
... This patient most likely has a CYP2D6 and CYP2C9 polymorphism The CYP2C9 polymorphism decreases her metabolic rate of coumadin, leading to a lower dose requirement for her goal INR of 2-3 The analgesic effect of morphine is decreased in CYP2D6 polymorphisms so she will require an analgesic tha ...
